Report Overview
Global Biosimilar Contract Manufacturing Market size is expected to be worth around US$ 22.0 Billion by 2035 from US$ 8.1 Billion in 2025, growing at a CAGR of 10.5% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 42.50% share with a revenue of US$ 3.21 Billion.
The global Biosimilar Contract Manufacturing Market is witnessing significant growth as pharmaceutical and biotechnology companies increasingly outsource the development and production of biosimilar medicines to specialized contract manufacturing organizations (CMOs). The market is projected to grow from US$ 8.1 billion in 2025 to approximately US$ 22.0 billion by 2035, registering a compound annual growth rate (CAGR) of 10.5% during the forecast period from 2026 to 2035.
The rising demand for cost-effective biologic therapies, increasing biosimilar approvals, and growing patent expirations of reference biologics are key factors supporting market expansion. Monoclonal antibodies are expected to remain the leading product segment, accounting for 47.8% of the market in 2025, while oncology is projected to dominate applications with a 38.5% share. Commercial manufacturing is anticipated to account for 52.6% of the market, reflecting the growing preference for outsourced large-scale production. Pharmaceutical companies are expected to remain the largest end users, holding 41.3% of the market share. North America is forecast to lead the global market in 2025, capturing 42.5% of the total market and generating approximately US$ 3.21 billion in revenue, driven by strong biologics manufacturing capabilities, advanced regulatory frameworks, and continued investment in biosimilar development.
Click here for more information: https://market.us/report/biosimilar-contract-manufacturing-market/
Key Takeaways
- Market Size: The global Biosimilar Contract Manufacturing Market is projected to grow from US$ 8.1 billion in 2025 to US$ 22.0 billion by 2035.
- Growth Rate: The market is expected to register a CAGR of 10.5% during the forecast period (2026–2035).
- By Product Type: Monoclonal antibodies are expected to lead the market with a 47.8% share in 2025.
- By Application: Oncology is projected to account for the largest share at 38.5% in 2025.
- By Service Type: Commercial manufacturing is anticipated to dominate with a 52.6% market share.
- By End User: Pharmaceutical companies are expected to hold the largest share, representing 41.3% of the market in 2025.
- By Region: North America is expected to remain the leading regional market, capturing 42.5% of the global share and generating US$ 3.21 billion in revenue in 2025.
Key Market Segments
- Market Size: The global Biosimilar Contract Manufacturing Market is projected to grow from US$ 8.1 billion in 2025 to US$ 22.0 billion by 2035.
- Growth Rate: The market is expected to register a CAGR of 10.5% during the forecast period (2026–2035).
- By Product Type: Monoclonal antibodies are expected to lead the market with a 47.8% share in 2025.
- By Application: Oncology is projected to account for the largest share at 38.5% in 2025.
- By Service Type: Commercial manufacturing is anticipated to dominate with a 52.6% market share.
- By End User: Pharmaceutical companies are expected to hold the largest share, representing 41.3% of the market in 2025.
- By Region: North America is expected to remain the leading regional market, capturing 42.5% of the global share and generating US$ 3.21 billion in revenue in 2025.
Market Key Players
- By Component
- Hardware
- Software
- Services
- By Technology
- Barcode Scanning
- Radio Frequency Identification (RFID)
- Near Field Communication (NFC)
- Others
- By Application
- Laboratory Specimens
- Anatomical Pathology Specimens
- Surgical and Biopsy Specimens
- Blood and Blood Products
- Reproductive Tissue and Gametes
- Others
- By End User
- Hospitals
- Diagnostic Laboratories
- Blood Banks
- Biobanks and Research Institutes
- Pathology Laboratories
- Others
- By System Type
- Standalone Systems
- Integrated Systems
Market Dynamics
Driver
The growing demand for affordable biologic therapies is a major driver of the biosimilar contract manufacturing market. Biologics are widely used to treat chronic diseases such as cancer, rheumatoid arthritis, diabetes, and inflammatory bowel disease, but their high production costs often limit patient access. Biosimilars provide comparable safety and efficacy at lower prices, encouraging healthcare systems to adopt them. According to the U.S. Food and Drug Administration (FDA), more than 70 biosimilars had been approved in the United States by 2025, with approvals increasing across oncology, immunology, and endocrinology.
The European Medicines Agency (EMA) has authorized 100+ biosimilar medicines since the first approval in 2006, demonstrating strong regulatory confidence in these products. As more reference biologics lose patent exclusivity, pharmaceutical companies increasingly rely on contract manufacturing organizations (CMOs) to provide advanced biologics production capacity while reducing capital investment. Contract manufacturers also help companies meet stringent Good Manufacturing Practice (GMP) requirements and accelerate commercialization. This combination of growing biosimilar approvals, increasing patient demand, and expanding outsourcing strategies continues to strengthen the global biosimilar contract manufacturing market.
Trend
A significant trend shaping the biosimilar contract manufacturing market is the rapid adoption of advanced bioprocessing technologies, including single-use bioreactors, continuous manufacturing, automation, and digital monitoring systems. These technologies improve production efficiency, reduce contamination risks, and shorten manufacturing timelines while maintaining product quality. According to the U.S. FDA, manufacturers are increasingly implementing advanced manufacturing technologies to enhance pharmaceutical production reliability and product consistency. Single-use systems can significantly reduce cleaning validation requirements and lower operational costs compared with traditional stainless-steel facilities. Additionally, digital manufacturing platforms and real-time analytics help optimize production performance and ensure regulatory compliance.
The National Institute of Standards and Technology (NIST) also supports the integration of advanced manufacturing technologies to improve pharmaceutical supply chain resilience and production quality. As biosimilar pipelines continue expanding worldwide, pharmaceutical companies increasingly seek CMOs equipped with flexible manufacturing platforms capable of producing multiple biologic products in smaller, efficient batches. This trend supports faster technology transfer, scalable production, and greater responsiveness to changing market demand while reducing facility investment and operational complexity.
Restraint
The biosimilar contract manufacturing market faces significant challenges due to the complexity of biologic production and strict regulatory requirements. Unlike conventional small-molecule drugs, biosimilars are manufactured using living cells, making production highly sensitive to changes in cell lines, raw materials, and manufacturing conditions. Even minor process variations can affect product quality, requiring extensive analytical characterization and comparability studies.
According to the World Health Organization (WHO), biosimilars must demonstrate high similarity to their reference products through comprehensive quality, non-clinical, and clinical evaluations before regulatory approval. Manufacturing facilities must also comply with current Good Manufacturing Practice (cGMP) standards established by agencies such as the FDA and EMA, requiring substantial investment in quality control systems, specialized equipment, and skilled personnel. Regulatory inspections, process validation, and documentation further increase production costs and timelines. Smaller biotechnology companies may find these investments financially challenging, leading to delays in commercialization or reliance on external manufacturing partners. These technical and regulatory complexities continue to act as key restraints on the growth and scalability of the biosimilar contract manufacturing market.
Opportunity
A major opportunity for the biosimilar contract manufacturing market lies in expanding global access to biologic medicines and the increasing number of biologic patent expirations. According to the World Health Organization (WHO), noncommunicable diseases account for approximately 41 million deaths annually, representing 74% of global deaths, creating sustained demand for biologic therapies to treat cancer, autoimmune disorders, and metabolic diseases. As numerous blockbuster biologics continue losing market exclusivity over the coming years, biosimilar developers are accelerating product development programs. Many emerging biotechnology companies lack dedicated large-scale biologics manufacturing facilities, increasing reliance on specialized CMOs for process development, clinical manufacturing, and commercial production.
Governments are also promoting biosimilar adoption to improve healthcare affordability and patient access. The European Commission and EMA continue supporting biosimilar use through regulatory guidance and educational initiatives that encourage confidence among healthcare professionals. These favorable healthcare policies, combined with rising chronic disease prevalence, expanding biosimilar pipelines, and increasing outsourcing by pharmaceutical companies, create substantial long-term growth opportunities for contract manufacturing organizations specializing in biosimilar production.
Conclusion
The global biosimilar contract manufacturing market is poised for robust growth, supported by the increasing demand for affordable biologic therapies, rising biosimilar approvals, and expanding outsourcing by pharmaceutical and biotechnology companies. Advances in bioprocessing technologies, including single-use systems, automation, and continuous manufacturing, are improving production efficiency and enabling contract manufacturers to meet stringent quality standards.
Although the market faces challenges related to complex manufacturing processes, high capital requirements, and rigorous regulatory compliance, these barriers are encouraging greater collaboration with specialized contract manufacturing organizations. Furthermore, the growing number of biologic patent expirations, increasing prevalence of chronic diseases, and government initiatives promoting biosimilar adoption are expected to create significant long-term opportunities. As healthcare systems worldwide focus on expanding patient access to cost-effective biologic treatments, contract manufacturers with advanced technological capabilities, regulatory expertise, and scalable production infrastructure will play a vital role in supporting biosimilar development and commercialization, driving sustained market growth over the forecast period.
Top comments (0)